Download FREE Report Sample
Download Free sampleLantus (insulin glargine) is an effective, long-acting insulin that provides all-day blood sugar control, but it can cause low blood sugar levels, so be sure to have a source of sugar nearby. Lowers blood sugar. Humalog (insulin lispro) is a fast-acting insulin that controls blood sugar around meal times.
Insulin Glargine and Lispro Market contains market size and forecasts of Insulin Glargine and Lispro in global, including the following market information:
Global Insulin Glargine and Lispro Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Insulin Glargine and Lispro Market Sales, 2017-2022, 2023-2028, (Liter)
Global top five Insulin Glargine and Lispro companies in 2021 (%)
The global Insulin Glargine and Lispro market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Branded Drug Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Insulin Glargine and Lispro include Sanofi S.A, Eli Lilly and Company, Biocon Limited, Cipla Limited, Gan & Lee Pharmaceutical Ltd., Julphar Diabetes LLC, Merck & Co., Novo Nordisk A/S and SAJA Pharmaceuticals and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Insulin Glargine and Lispro manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Insulin Glargine and Lispro Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Liter)
Global Insulin Glargine and Lispro Market Segment Percentages, by Type, 2021 (%)
Branded Drug
Biosimilar Drug
Global Insulin Glargine and Lispro Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Liter)
Global Insulin Glargine and Lispro Market Segment Percentages, by Application, 2021 (%)
Type I Dibetes
Type II Dibetes
Global Insulin Glargine and Lispro Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Liter)
Global Insulin Glargine and Lispro Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Insulin Glargine and Lispro revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Insulin Glargine and Lispro revenues share in global market, 2021 (%)
Key companies Insulin Glargine and Lispro sales in global market, 2017-2022 (Estimated), (Liter)
Key companies Insulin Glargine and Lispro sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi S.A
Eli Lilly and Company
Biocon Limited
Cipla Limited
Gan & Lee Pharmaceutical Ltd.
Julphar Diabetes LLC
Merck & Co.
Novo Nordisk A/S
SAJA Pharmaceuticals
Wockhardt Ltd.
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
